New drug combo trial offers hope for Tough-to-Treat blood cancer
NCT ID NCT07209163
Summary
This study is testing whether a combination of three targeted drugs (tazemetostat, linperlisib, and golidocitinib) can help control a rare and aggressive blood cancer called peripheral T-cell lymphoma in patients whose disease has returned or not responded to prior treatment. The main goal is to see if this combination is safe and can shrink tumors. It will enroll about 48 adults who have had at least one prior treatment and are not eligible for a stem cell transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.